Affimed to present efficacy results of NSCLC combination therapy

Affimed (AFMD) will present an update from the company’s AFM24-102 study in advanced EGFR wild-type – EGFRwt – non-small cell lung cancer at the annual American Society of Clinical Oncology meeting in Chicago May 31 – June 4. Patients in the study are treated with the combination of AFM24, Affimed’s innate cell engager, and atezolizumab, Roche’s (RHHMBY) checkpoint inhibitor. One patient showed a confirmed complete response, and three patients showed confirmed partial responses. In addition, seven patients achieved stable disease, resulting in a disease control rate of 73.3% or 11/15 patients. Median progression-free survival was 5.9 months. All responders were resistant to checkpoint inhibitor treatment prior to the study, which supports the hypothesis that combining AFM24 with atezolizumab may enhance the cancer-immunity cycle and provide an alternative strategy to overcome resistance to existing therapies for EGFR-expressing tumors.Treatment in these heavily pretreated patients was well tolerated. Side effects were consistent with the known safety profiles of these agents. The EGFRwt NSCLC cohort of the study will enroll up to 40 patients and the EGFRmut NSCLC cohort will enroll up to 25 patients.